Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges* (Roche)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will be a randomized, double blind, placebo-controlled, parallel group study and will include subjects with ragweed-induced seasonal allergic rhinitis.
| Condition | Intervention |
|---|---|
|
Allergy |
Drug: Fluticasone Drug: Fluticason |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges* |
- Effect of nasal allergen challenges on biomarkers [ Time Frame: December 2011 ] [ Designated as safety issue: No ]
| Enrollment: | 60 |
| Study Start Date: | November 2010 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: montelukast
luekotriene inhibitor
|
Drug: Fluticasone
nasal spray
|
|
Active Comparator: Fluticasone
Nasal steroid
|
Drug: Fluticason
2 sprays per day in each nostril
|
Detailed Description:
The primary goal of this proposal is to assess the ability of an intranasal corticosteroid, fluticasone, and montelukast to affect the upper airway and systemic physiologic, biologic and clinical parameters occurring after an early and late upper airway allergic response to ragweed in ragweed allergic rhiniticsThe assessment of early allergy responses in the nose has been fairly well established in our laboratory and we will use methods detailed in previous publications (21, 23 24). One potential challenge will be to sample upper airway mediators and cytokines without affecting clinical parameters such as symptom scores and acoustic rhinometry readings. Moreover, we will need to sample at time points throughout six or more hours in order to accurately determine the effects on late phase allergic responses. Nasal filter paper sampling is a technique that we are currently engaged in using, and we will work with Roche to elute the samples and measure multiple mediators and cytokines.
Eligibility| Ages Eligible for Study: | 19 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or female subjects aged 19-60 years.
- Females of child bearing potential must use appropriate birth control throughout the study and urine pregnancy tests must be negative prior to dosing at each study visit.
- Subjects with a documented history of ragweed-induced seasonal allergic rhinitis requiring pharmacotherapy during the preceding 2 allergen seasons.
- Subjects with a positive skin prick test to short ragweed (Amb a 1) extract, defined as >3mm wheal larger than saline control
- Subjects spirometry FEV1 must be > 80% predicted prior to each allergen challenge
- Subjects average post diluents nasal congestion score must be < 1 at admission for each study visit
Exclusion Criteria:
- Subjects with evidence or history of clinically significant medical illnesses other than changes related to allergic rhinitis. Subjects with some stable chronic medical conditions not expected to interfere with the conduct or safety of the study may be eligible to participate based on the investigator's discretion.
- Subjects with a history of asthma or urticaria, or a screening FEV1 prior to allergen challenge of <80% of predicted. in FEV1 compared to pre-diluent FEV1 baseline at either screening visit.
- Subjects with significant nasal deformity, recent nasal surgery nasal polyps or chronic rhinosinusitis.
- Subjects who have smoked in the last 6 months or have a history of >10 pack years.
- Subjects who are taking or have taken restricted concomitant medications that could confound the safety or efficacy assessments including those shown below.
- Subjects who have history or evidence of alcohol or drug abuse.
- Subjects exposed to cat and have a positive skin test to cat.
- Subjects that have a positive skin test to dust mite (D pteronyssinus/ D farinae) requiring pharmacotherapy
Contacts and Locations| United States, Nebraska | |
| Creighton University Medical Center | |
| Omaha, Nebraska, United States, 68131 | |
| Principal Investigator: | Thomas B Casale, MD | Creighton University |
More Information
Publications:
| Responsible Party: | Thomas B. Casasle, MD, Creighton University |
| ClinicalTrials.gov Identifier: | NCT01240889 History of Changes |
| Other Study ID Numbers: | 10-15912 |
| Study First Received: | October 28, 2010 |
| Last Updated: | October 8, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Creighton University:
|
Ragweed allergies acoustic rhinometry nasal allergen challenge |
Additional relevant MeSH terms:
|
Hypersensitivity Immune System Diseases Fluticasone Montelukast Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Dermatologic Agents Anti-Allergic Agents Anti-Inflammatory Agents Leukotriene Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists |
ClinicalTrials.gov processed this record on May 19, 2013